ECOA, ESource and Clinical Trials Market Report 2025

The eCOA, eSource and clinical trials market size has grown strongly in recent years. It will grow from $47.83 billion in 2024 to $51.48 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to adoption of electronic data capture in clinical trials, evolution of regulatory standards for electronic clinical outcome assessments (ecoa), growth of mobile and wearable health technology, increase in complexity and scale of clinical trials, emphasis on patient-centric approaches in clinical research.

The eCOA, eSource and clinical trials market size is expected to see strong growth in the next few years. It will grow to $74.93 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expansion of global clinical trial networks, rise in demand for real-time data access and monitoring, development of cloud-based eclinical solutions, growth of remote and virtual patient monitoring solutions, increase in the use of electronic patient-reported outcomes, rise in demand for wearables for continuous patient monitoring, surge in adoption of mobile health apps for patient engagement, emphasis on user-friendly and patient-centric ecoa designs. Major trends in the forecast period include technological advancements in esource solutions, adoption of blockchain for secure and transparent clinical data management, adoption of artificial intelligence for data analysis in clinical research, integration of machine learning for predictive analytics in clinical trials, development of decentralized clinical trial ecosystems.

The anticipated surge in clinical trials is expected to drive the growth of the eCOA, eSource, and clinical trials market. Clinical trials, which are research studies assessing the safety and efficacy of new medical interventions or treatment approaches, can benefit from the use of eCOA and eSource solutions. These technologies enable pharmaceutical companies to expedite trials, conducting them more efficiently within shorter time frames. eCOA solutions replace traditional paper-based patient-reported outcomes by employing innovative technologies for collecting clinical outcome data. For example, a report published on ClinicalTrials.gov in June 2023, a US-based registry of clinical trials run by the United States National Library of Medicine, projects the number of registered studies to reach 457,100 in 2023, a substantial increase from 362,479 in 2020. Thus, the growing demand for more clinical trials is a driving force behind the expansion of the eCOA, eSource, and clinical trials market.

The increasing adoption of cloud-based solutions is poised to propel the future growth of the eCOA, eSource, and clinical trials market. Cloud-based solutions encompass programs, storage spaces, on-demand services, computer networks, and other services accessible through a shared cloud computing framework via an internet connection. These solutions streamline eCOA (electronic Clinical Outcome Assessments) and eSource in clinical trials by facilitating real-time data capture, secure storage, and remote accessibility, ultimately optimizing trial efficiency and ensuring data accuracy. As an example, according to the Australian Bureau of Statistics in June 2023, an Australia-based government agency for statistics, 85% of firms reported employing information and communication technologies (ICTs) for the year ending June 30, 2022, up from 69% during the year ending June 30, 2020, with 59% related to cloud computing. Hence, the increasing adoption of cloud-based solutions is a driving factor for the growth of the eCOA, eSource, and clinical trials market.

Technological advancements constitute a prominent trend gaining traction in the eCOA, eSource, and clinical trials market. Leading companies in these markets are actively engaged in introducing innovative technologies to maintain their competitive positions. For example, in May 2022, Clinical Research IO, a US-based developer of eSource solutions, unveiled CRIO Reviewer, an industry-first solution designed to establish a fully integrated eSource or EDC (electronic data capture) system. This solution facilitates the review and coding of data collected by the CRIO eSource application, utilizing CRIO's web-based resource technology to optimize site workflows in clinical data management. As the first commercial system designed for site processes, CRIO Reviewer aims to make real-time electronic data gathering more accessible for sites.

Major companies in the eCOA, eSource, and clinical trials market are concentrating on introducing electronic health record (EHR) eSource solutions to streamline data collection, enhance accuracy, and improve the efficiency of clinical trial processes. An EHR eSource solution refers to a system or technology that facilitates the direct collection, integration, and use of health data from electronic sources, such as EHRs, for research, clinical trials, and regulatory purposes. For example, in January 2022, OpenClinica, LLC, a US-based company, launched OpenClinica Unite, an EHR eSource solution. This platform allows research teams to pre-populate electronic case report forms (eCRFs) with patient data from EHRs with a single click, reducing the time spent on manual data entry and minimizing transcription errors. By ensuring that the data in the electronic data capture (EDC) system aligns with that in the EHR, OpenClinica Unite removes the need for source data verification (SDV) for those items, resulting in more accurate and comprehensive datasets.

In August 2023, Sitero LLC, a US-based company, acquired Clario's eClinical technology suite for an undisclosed sum. This acquisition enables Sitero to broaden its portfolio by integrating Clario's expertise in electronic Clinical Outcome Assessment (eCOA), eSource, and clinical trials. Clario Co. is a US-based company that significantly contributes to the advancement of clinical trials through its innovative eCOA and eSource solutions.

Major companies operating in the eCOA, eSource and clinical trials market include The International Business Machines Corporation, Oracle Corporation, Laboratory Corporation of America Holdings, IQVIA Inc., Icon PLC, PPD Inc., Syneos Health Inc, Parexel International Corporation, Medpace Holdings Inc., TransPerfect Life Sciences, Medidata Solutions Inc., Signant Health Private Limited, Clario, Advarra Inc., Medable Inc., ArisGlobal LLC, Kayentis SAS, YPrime LLC, Clinical Ink, Cloudbyz Inc., Medrio Inc., OpenClinica LLC, Castor EDC, Clinipace Inc.

North America was the largest region in the eCOA, eSource and clinical trials market in 2024. The regions covered in the ecoa, esource and clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ecoa, esource and clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Electronic Clinical Outcome Assessment (eCOA) involves employing electronic methods and technologies for the collection, management, and analysis of clinical outcome assessment data in clinical trials and various healthcare research settings. Simultaneously, eSource refers to the utilization of electronic systems to capture, manage, and store data generated during clinical trials. Clinical trials, which are research studies designed to assess the safety, efficacy, and effectiveness of new medical interventions, benefit from the incorporation of eCOA and eSource, enhancing the efficiency, accuracy, and reliability of data collection and management processes.

The primary solution categories encompassed by eCOA, eSource, and clinical trials include eCOA (Electronic Clinical Outcome Assessment), eSource, clinical trial solutions, and electronic data capture (EDC). eCOA, specifically, entails utilizing electronic systems and devices to capture, manage, and analyze patient-reported outcome measures within clinical trials and healthcare settings. This solution can be deployed in both licensed enterprise (on-premise) and cloud-based (SAAS) environments, catering to diverse end users such as hospitals, healthcare providers, Contract Research Organizations (CROs), the pharmaceutical industry, the biotechnology industry, the medical device industry, and others.

The eCOA, eSource and clinical trials market research report is one of a series of new reports that provides eCOA, eSource and clinical trials market statistics, including eCOA, eSource and clinical trials industry global market size, regional shares, competitors with a eCOA, eSource and clinical trials market share, detailed eCOA, eSource and clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the eCOA, eSource and clinical trials industry. This eCOA, eSource and clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eCOA, eSource, and clinical trials markets include revenues earned by entities by providing pre-built assessments, real-time patient data, and project documentation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.